Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) FCF Margin (2016 - 2025)

Historic FCF Margin for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to 461.67%.

  • Guided Therapeutics' FCF Margin changed N/A to 461.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 623.03%, marking a year-over-year increase of 23322300.0%. This contributed to the annual value of 15985.71% for FY2024, which is 142040800.0% down from last year.
  • Guided Therapeutics' FCF Margin amounted to 461.67% in Q3 2025.
  • Guided Therapeutics' FCF Margin's 5-year high stood at 258.33% during Q4 2021, with a 5-year trough of 34800.0% in Q2 2021.
  • For the 5-year period, Guided Therapeutics' FCF Margin averaged around 8440.3%, with its median value being 2268.18% (2023).
  • As far as peak fluctuations go, Guided Therapeutics' FCF Margin surged by 274800000bps in 2022, and later crashed by -321500000bps in 2024.
  • Guided Therapeutics' FCF Margin (Quarter) stood at 258.33% in 2021, then tumbled by -7958bps to 20300.0% in 2022, then soared by 95bps to 1050.0% in 2023, then plummeted by -3062bps to 33200.0% in 2024, then surged by 99bps to 461.67% in 2025.
  • Its last three reported values are 461.67% in Q3 2025, 144.44% for Q2 2025, and 33200.0% during Q4 2024.